NCT07127926 Evaluation of Belumosudil Whole Tablets vs. Crushed Tablets Pharmacokinetics in Patients Suffering From Chronic GvHD
| NCT ID | NCT07127926 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Chronic Graft Versus Host Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 8 participants |
| Start Date | 2026-02-09 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 8 participants in total. It began in 2026-02-09 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary objective of the study is to evaluate belumosudil pharmacokinetics of whole tablets and crushed tablets suspended in water in patients suffering from chronic graft-versus-host disease (cGVHD).
Eligibility Criteria
Inclusion Criteria: * Male and female subjects ≥ 18 years of age with allogeneic HSCT Exclusion Criteria: * Receiving an investigational GVHD treatment within 28 days of study entry; (2) active acute GVHD; and (3) taking any medication known to be CYP3A4 inducers. * Pregnancy is an exclusion criterion for stem cell transplant. Pregnant women are not included in this study. Non-viable neonates will not be included in this study. Patients with cognitive impairments will not be included in this study. Patients aged less than 18 years old will not be included.
Contact & Investigator
Amin Alousi, MD
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT07127926 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Graft Versus Host Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07127926 currently recruiting?
Yes, NCT07127926 is actively recruiting participants. Contact the research team at aalousi@mdanderson.org for enrollment information.
Where is the NCT07127926 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT07127926 clinical trial?
NCT07127926 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Amin Alousi, MD at M.D. Anderson Cancer Center. The trial plans to enroll 8 participants.